How does venture debt complement equity financing for startups, and what role do warrants play in the lender's return?

Venture debt is a specialized form of lending to venture-backed startups, typically structured as a term loan with warrant coverage. It extends a company's cash runway between equity rounds without diluting existing shareholders. Lenders underwrite based on the strength of the equity investor base and the company's growth trajectory rather than traditional cash flow metrics.\n\nWhy Founders Choose Venture Debt:\n\nVenturePath Biotech just raised a $30 million Series B at a $150 million pre-money valuation. They need an additional $10 million to reach profitability milestones before their Series C.\n\nOption A — Raise more equity: Sell $10M of additional shares, diluting existing shareholders by approximately 6.3% ($10M / $160M post-money).\n\nOption B — Venture debt: Borrow $10M with 8% of warrant coverage, diluting shareholders by approximately 0.5% ($800K / $160M).\n\nFounder dilution savings: 6.3% - 0.5% = 5.8 percentage points preserved — worth approximately $8.7 million at current valuation.\n\nTypical Venture Debt Terms:\n\n| Parameter | Typical Range |\n|---|---|\n| Loan size | 25-35% of last equity round |\n| Interest rate | Prime + 3-6% (currently ~11-14%) |\n| Term | 36-48 months |\n| Interest-only period | 6-12 months |\n| Warrant coverage | 5-15% of loan value |\n| Warrant strike price | Latest equity round price |\n| Covenants | Minimum cash balance, milestone-based |\n\nLender Return Mechanics:\n\nCedargrove Lending provides the $10M loan to VenturePath:\n- Interest: 12% on $10M = $1.2M/year\n- Warrant coverage: 8% x $10M = $800K worth of warrants at Series B price\n- If VenturePath exits at $600M (4x from Series B):\n - Warrant value: $800K x 4 = $3.2M (net $2.4M gain)\n - Total return: $3.6M interest (3 years) + $2.4M warrant gain = $6.0M on $10M deployed\n - Gross IRR: approximately 22%\n- If VenturePath fails (total loss):\n - Recovery on assets and IP: perhaps $1.5M (15% recovery)\n - Net loss: $8.5M\n\nUnderwriting Framework:\nVenture lenders evaluate:\n1. Quality of equity sponsors (top-tier VCs have higher follow-on rates)\n2. Months of runway the debt provides (target: 6-9 months extension)\n3. Path to next milestone (revenue target, clinical trial, product launch)\n4. Liquidation value of tangible and intellectual property\n\nExplore venture financing structures in our CFA Alternative Investments course.